PepCan

PepCan is a therapeutic vaccine candidate developed for the treatment of Human Papillomavirus (HPV) 16-positive cervical intraepithelial neoplasia (CIN) 2/3. The vaccine formulation consists of four synthetic long peptides (SLPs) covering the entire sequence of the HPV 16 E6 oncoprotein. It is administered intradermally with *Candida albicans* skin test antigen, which serves as a novel adjuvant to enhance the cellular immune response. By stimulating HPV 16 E6-specific T-cell activity, PepCan aims to induce the regression of high-grade cervical lesions and clear persistent HPV infection. The vaccine was developed by researchers at the University of Arkansas for Medical Sciences (UAMS).

Brand names

PepCan

Other names

HPV 16 E6 peptide vaccineHPV16 E6 peptide vaccineHPV-16 E6 peptide vaccineHPV 16 E6 SLP vaccineHPV16 E6 SLP vaccineHPV-16 E6 SLP vaccine